Volume 17, Issue 4 (2-2004)                   Med J Islam Repub Iran 2004 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

FALLAHZADEH M H, GHAMAR H. LOW DOSE PREDNISOLONE WITH INCREASE IN DOSAGE INTERVAL IN FREQUENT RELAPSING NEPHROTIC SYNDROME. Med J Islam Repub Iran 2004; 17 (4) :305-308
URL: http://mjiri.iums.ac.ir/article-1-1617-en.html
From the Department of Pediatrics, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran , fallahzadeh@dr.com
Abstract:   (4282 Views)
In order to avoid using cytotoxic drugs and to minimize prednisolone side effects in frequent relapsing or steroid-dependent idiopathic nephrotic syndrome, 35 patients, 3 to 15 (mean= 8.1) years of age, were studied. While in remission for at least 6 weeks, the dose of prednisolone was reduced to 0.1-0.37 (mean= 0.23) mg/kg/day as a single dose for 12 to 72 (mean= 27.6) months. It was followed by a tapering method, with gradual increase in the interval instead of decrease in the dose for about 10 to 12 months, and about 18.4 months follow-up without treatment. About 54.3% of the patients had no relapse during the treatment period and the relapse rate per patient per year was 3.94 during the preceding 12 months before the study, 0.51 during treatment (p<0.001) and 0.23 after discontinuation of the drug. Each relapse was treated by a standard dose of prednisolone for 2 months and then the low dose regimen was resumed. The patients tolerated the drug well with minimal side effects. It is concluded that long term, low-dose daily prednisolone therapy followed by gradual increase in the interval is a safe, well-tolerated and effective method of maintaining prolonged remission in most children with frequent relapsing idiopathic nephrotic syndrome.
Full-Text [PDF 391 kb]   (1745 Downloads)    
Type of Study: Original Research | Subject: Pediatric

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.